Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

8.0%

11 terminated/withdrawn out of 137 trials

Success Rate

88.2%

+1.6% vs industry average

Late-Stage Pipeline

7%

9 trials in Phase 3/4

Results Transparency

48%

39 of 82 completed trials have results

Key Signals

23 recruiting39 with results7 terminated4 withdrawn

Enrollment Performance

Analytics

Phase 2
33(37.1%)
N/A
31(34.8%)
Phase 1
15(16.9%)
Phase 3
6(6.7%)
Phase 4
3(3.4%)
Early Phase 1
1(1.1%)
89Total
Phase 2(33)
N/A(31)
Phase 1(15)
Phase 3(6)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (137)

Showing 20 of 137 trials
NCT06164756Completed

Long Term Follow Up KET-PD

Role: collaborator

NCT07610369Phase 2Recruiting

The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease

Role: collaborator

NCT07830654Phase 2Recruiting

This Protocol is a Sub-study Under the PPMI Program. It is a Longitudinal, Single-center Study to Assess the Performance of [18F]AV-133 Imaging Using High and Standard Resolution PET in Individuals Enrolled With Parkinson's Disease (PD) for up to 12 Months.

Role: lead

NCT07005180Phase 2Recruiting

Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease

Role: collaborator

NCT07630545Phase 1Recruiting

A Phase I Study in Healthy Volunteers and Parkinson's Disease (PD) Patients.

Role: collaborator

NCT05904288Completed

DTx Algorithms for Personalized Parkinson's Disease Treatment and Medication Plan Optimization

Role: collaborator

NCT07809438Phase 2Recruiting

A Comparative Performance Study Between High and Standard Resolution Positron Emission Tomography Camera Using [18F] AV-133 in Prodromal Parkinson's Disease

Role: lead

NCT05065060Recruiting

Parkinson Progression Marker Initiative Online (PPMI Online)

Role: lead

NCT04506073Phase 2Completed

Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson's Disease

Role: collaborator

NCT04101968Completed

The GBA Multimodal Study in Parkinson's Disease

Role: collaborator

NCT06193252Not ApplicableRecruiting

Slow-SPEED-NL: Slowing Parkinson's Early Through Exercise Dosage-Netherlands

Role: collaborator

NCT06993142Not ApplicableRecruiting

Slow-SPEED: Slowing Parkinson's Early Through Exercise Dosage

Role: collaborator

NCT07705373Not ApplicableRecruiting

A Novel Digital Music-based Autonomous Personalized Walking Intervention to Improve Gait and Walking Automaticity in Parkinson Disease

Role: collaborator

NCT07781696Not ApplicableNot Yet Recruiting

CnF-DBS for Levodopa-Resistant FOG

Role: collaborator

NCT06289582Early Phase 1Recruiting

Longitudinal TSPO PET Imaging With [18F]DPA-714 in PPMI (PPMI DPA-714 PET Imaging)

Role: collaborator

NCT07020026Phase 2Recruiting

Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease

Role: lead

NCT04477785Recruiting

PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort

Role: lead

NCT07026929Active Not Recruiting

Neuro-immune Interactome in Parkinson's Disease

Role: collaborator

NCT07142044Phase 1Recruiting

Safety, Tolerability and Exploratory Efficacy of EC5026 in Parkinson's Disease (STEP Study)

Role: collaborator

NCT07642908Recruiting

Striatal and Extra-Striatal Cholinergic Terminal Density in LRRK2-PD Mutation

Role: collaborator